Skip to content
CompletedPhase 2Results posted

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200 · P-TRD · COMPASS Pathways

Closed to entry
Status
Not accepting participants
Phase 2
Phase
233
Target enrolment
25
Study sites
6 US states

What it is testing

Summary

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3

    Measured over Change from Baseline to Week 3

  • MADRS Change From Baseline to Week 3, Sensitivity Analysis

    Measured over Change from Baseline to Week 3

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Diagnosis of TRD Exclusion Criteria: * Other comorbidities

Where

25 study sites

FacilityCityRegionCountry
Kadima Neuropsychiatry InstituteLa JollaCaliforniaUnited States
Altman Clinical and Translational Research Institute, University of CaliforniaSan DiegoCaliforniaUnited States
Stanford Department of PsychiatryStanfordCaliforniaUnited States
Mood and Anxiety Disorders Program Emory University School of MedicineAtlantaGeorgiaUnited States
Ray Worthy Psychiatry LLCNew OrleansLouisianaUnited States
Sheppard Pratt Health SystemBaltimoreMarylandUnited States
New York State Psychiatric InstituteNew YorkNew YorkUnited States
UT Center of Excellence on Mood Disorders, University of Texas Health Science CenterHoustonTexasUnited States
Canadian Rapid Treatment Centre of ExcellenceMississaugaOntarioCanada
Centre for Addiction and Mental HealthTorontoOntarioCanada
National Institute of Mental Health Czech RepublicKlecanyCzechia
Enhed for Psykiatrisk Forskning, Psykiatrien i AalborgAalborgDenmark
Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin FranklinBerlinGermany
Tallaght University HospitalDublinIreland
Groningen University Medical CentreGroningenNetherlands
Leiden University Medical CentreLeidenNetherlands
Utrecht University Medical CentreUtrechtNetherlands
Unidade de Neuropsiquiatria, Centro Clinico ChampalimaudLisbonPortugal
Hospital de Dia NumanciaBarcelonaSpain
Institute Hospital del Mar of Medical Research (IMIM)BarcelonaSpain
Clinical Research and Imaging CentreBristolAvonUnited Kingdom
Wolfson Research Centre, Campus for Ageing and VitalityNewcastle upon TyneTyne and WearUnited Kingdom
St. Pancras Clinical ResearchLondonUnited Kingdom
Kings College London, Institute of Psychiatry, Psychology and NeurologyLondonUnited Kingdom
Greater Manchester Mental Health Foundation TrustManchesterUnited Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03775200 on ClinicalTrials.gov →

Last updated in the registry 2023-04-24. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits